- Home
- GPI vs IONS Comparison
GPI vs IONS Comparison
Compare GPI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPI
- IONS
- Stock Information
- Founded
- GPI 1995
- IONS 1989
- Country
- GPI United States
- IONS United States
- Employees
- GPI N/A
- IONS N/A
- Industry
- GPI Retail-Auto Dealers and Gas Stations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- GPI Consumer Discretionary
- IONS Health Care
- Exchange
- GPI Nasdaq
- IONS Nasdaq
- Market Cap
- GPI 5.7B
- IONS 6.0B
- IPO Year
- GPI 1997
- IONS 1991
- Fundamental
- Price
- GPI $419.76
- IONS $36.17
- Analyst Decision
- GPI Strong Buy
- IONS Buy
- Analyst Count
- GPI 8
- IONS 18
- Target Price
- GPI $428.88
- IONS $62.00
- AVG Volume (30 Days)
- GPI 137.4K
- IONS 1.7M
- Earning Date
- GPI 01-29-2025
- IONS 02-19-2025
- Dividend Yield
- GPI 0.45%
- IONS N/A
- EPS Growth
- GPI N/A
- IONS N/A
- EPS
- GPI 37.54
- IONS N/A
- Revenue
- GPI $18,868,200,000.00
- IONS $803,067,000.00
- Revenue This Year
- GPI $10.46
- IONS N/A
- Revenue Next Year
- GPI $11.54
- IONS $19.61
- P/E Ratio
- GPI $11.21
- IONS N/A
- Revenue Growth
- GPI 8.05
- IONS 30.57
- 52 Week Low
- GPI $255.73
- IONS $33.33
- 52 Week High
- GPI $440.32
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- GPI 53.17
- IONS 41.84
- Support Level
- GPI $410.99
- IONS $36.39
- Resistance Level
- GPI $431.83
- IONS $38.90
- Average True Range (ATR)
- GPI 8.59
- IONS 1.52
- MACD
- GPI -3.25
- IONS -0.08
- Stochastic Oscillator
- GPI 31.55
- IONS 6.61
About GPI Group 1 Automotive Inc.
As of October, Group 1 owns and operates 44 collision centers and 260 automotive dealerships in the us and the UK, offering 35 brands of automobiles altogether. About 150 of the stores are in the us with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 38% of new-vehicle unit volume in 2023 and the UK about 19%. Texas, Oklahoma, and Massachusetts combined was 53%. Revenue in 2023 totaled $17.9 billion. The August, Inchcape UK deal adds about $2.7 billion of annual revenue and 54 stores to bring the UK store count to 114. Group 1 was founded in 1995 and is based in Houston.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.